2022 (v1)
Publication
No description
Uploaded on: February 6, 2024
-
-
2021 (v1)Publication
Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed...
Uploaded on: March 27, 2023